Search Beyond News…

GeneDx faces securities class action with August 3 lead‑plaintiff deadline

Executive summary: A securities fraud class action lawsuit was filed against GeneDx Holdings Corp. (NASDAQ: WGS), and Hagens Berman is inviting investors with significant losses to serve as lead plaintiff, with a deadline of August 3, 2026. The lawsuit exposes GeneDx to potential legal costs, settlement payments, and heightened regulatory scrutiny, while signaling increased shareholder litigation risk in the biotech sector.

Who is involved: GeneDx Holdings Corp., its investors who suffered losses, and the law firm Hagens Berman Sobol Shapiro LLP.

Likely next: Investors may submit lead plaintiff applications by the August 3 deadline; if appointed, the case will proceed to discovery and could result in a settlement or trial.

Hagens Berman Sobol Shapiro LLP announced that a securities fraud class action lawsuit has been filed against GeneDx Holdings Corp., urging investors with substantial losses to come forward. The notice sets an August 3, 2026 deadline for lead plaintiff applications, marking a procedural step in the litigation. The alert reflects a broader pattern of similar shareholder actions filed by the same law firm against several public companies on the same day.

Timeline

Analysis — what this means

Likely next events

Sectors affected

Regulatory implications

Historical parallels

Key entities

Sources

Related cases

Browse the full archive →